Virtus Biotech ETF (BBP) is a publicly traded the market company. As of May 21, 2026, BBP trades at $90.21 with a market cap of $0 and a P/E ratio of 0.00. BBP moved +3.43% today. Year to date, BBP is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces BBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ETF’s 4.03% ImmunityBio Holding Rises on Regulatory Plan and 700% Revenue Growth: Virtus LifeSci Biotech Products ETF holds ImmunityBio at a 4.03% weight, with shares up 1.51% following plans to submit a regulatory package for recombinant BCG in Saudi Arabia. ImmunityBio’s 113 million revenue for fiscal 2025 (+700% yoy) and Phase 2b NSCLC data (14.1-month median OS) bolster BBP’s biotech exposure.
| Metric | Value |
|---|---|
| Price | $90.21 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 140.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
BBP analyst coverage data. Average price target: $0.00.